Molecular basis of the anti-cancer effects of genistein isoflavone in LNCaP prostate cancer cells

Authors

  • K. Merchant College of Health Sciences, Barry University, 11300 NE 2nd Ave Miami Shores FL 33161
  • J. Kumi-Diaka Department of Biological Sciences, Florida Atlantic University, 3200 College Ave Davie FL 33314
  • A. Rathinavelu Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern University, Plantation Fl, 33322
  • N. Esiobu Department of Biological Sciences, Florida Atlantic University, 3200 College Ave Davie FL 33314
  • R. Zoeller Department of Health & Exercise Sci, Florida Atlantic University, 3200 College Ave Davie FL 33314
  • J. Hartmann Department of Biological Sciences, Florida Atlantic University, 3200 College Ave Davie FL 33314
  • M. Johnson Department of Biological Sciences, Florida Atlantic University, 3200 College Ave Davie FL 33314

DOI:

https://doi.org/10.31989/ffhd.v1i3.137

Abstract

Background: Prostate cancer is the most common form of non-skin cancer within the United States and the second leading cause of cancer deaths. Survival rates for the advanced disease remain relatively low, and conventional treatments may be accompanied by significant side effects. As a result, current research is aimed at alternative or adjuvant treatments that will target components of the signal transduction, cell-cycle and apoptosis pathways, to induce cell death with little or no toxic side effects to the patient. In this study, we investigated the effect of genistein isoflavone, a soy derivative, on expression levels of genes involved in these pathways. The mechanism of genistein-induced cell death was also investigated. The chemosensitivity of the LNCaP prostate cancer cells to genistein was investigated using ATP and MTS assays, and a caspase binding assay was used to determine apoptosis induction. Several molecular targets were determined using cDNA microarray and RT-PCR analysis.

Results: The overall data revealed that genistein induces cell death in a time- and dose-dependent manner, and regulates expression levels of several genes involved in carcinogenesis and immunity. Several cell-cycle genes were down-regulated, including the mitotic kinesins, cyclins and cyclin-dependent kinases. Various members of the Bcl-2 family of apoptotic proteins were also affected. The DefB1 and the HLA membrane receptor genes involved in immunogenicity were also up-regulated. 

Conclusion: The results indicate that genistein inhibits growth of the hormone-dependent prostate cancer cells, LNCaP, via apoptosis induction through regulation of some of the genes involved in carcinogenesis of many tumors, and immunogenicity. This study augments the potential phytotherapeutic and immunotherapeutic significance of genistein isoflavone.

Key words: Genistein isoflavone, prostate cancer, expression of genes, phytotherapeutic adjuvant, immunotherapy and chemotherapy

Downloads

Published

2011-03-31

Issue

Vol. 1 No. 3 (2011): March 2011

Section

Research Articles

License

Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request. 

 

Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.